CLLU1 as an emerging biomarker in chronic lymphoid leukemia.
Biomarker
CLLU1
Chronic lymphoid leukemia
Non-coding RNA
Prognosis
Journal
Human cell
ISSN: 1749-0774
Titre abrégé: Hum Cell
Pays: Japan
ID NLM: 8912329
Informations de publication
Date de publication:
20 Mar 2024
20 Mar 2024
Historique:
received:
18
11
2023
accepted:
26
02
2024
medline:
20
3
2024
pubmed:
20
3
2024
entrez:
20
3
2024
Statut:
aheadofprint
Résumé
CLLU1, a disease-specific gene associated with chronic lymphoid leukemia (CLL), is located on chromosome 12q22. Previous studies considered CLLU1 to be a non-coding RNA; however, recent research has discovered that its coding sequence region possesses the potential to encode a short peptide similar to interleukin-4. Remarkably, abnormally elevated expression of CLLU1 has only been detected in chronic lymphoid leukemia among all hematological cancers. High CLLU1 expression often indicates more malignant pathological features and an unfavorable prognosis for patients. Importantly, the expression level of CLLU1 remains unaffected by the passage of time or therapeutic interventions, thus rendering it a novel prognostic marker. This article provides a comprehensive summary of relevant research findings on CLLU1 in the context of CLL prognosis and clinical applications, aiming to guide subsequent theoretical and clinical investigations in this field.
Identifiants
pubmed: 38507118
doi: 10.1007/s13577-024-01051-4
pii: 10.1007/s13577-024-01051-4
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : the Natural Science Foundation project of Ningbo Science and Technology Bureau
ID : 2022J040
Informations de copyright
© 2024. The Author(s) under exclusive licence to Japan Human Cell Society.
Références
Hallek M, Al-Sawaf O. Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures. Am J Hematol. 2021;96:1679–705. https://doi.org/10.1002/ajh.26367 .
doi: 10.1002/ajh.26367
pubmed: 34625994
Pekarsky Y, Zanesi N, Croce CM. Molecular basis of CLL. Semin Cancer Biol. 2010;20:370–6. https://doi.org/10.1016/j.semcancer.2010.09.003 .
doi: 10.1016/j.semcancer.2010.09.003
pubmed: 20863894
pmcid: 2997849
Sevov M, Rosenquist R, Mansouri L. RNA-based markers as prognostic factors in chronic lymphocytic leukemia. Expert Rev Hematol. 2012;5:69–79. https://doi.org/10.1586/ehm.11.80 .
doi: 10.1586/ehm.11.80
pubmed: 22272707
Zhang S, Kipps TJ. The pathogenesis of chronic lymphocytic leukemia. Annu Rev Pathol. 2014;9:103–18. https://doi.org/10.1146/annurev-pathol-020712-163955 .
doi: 10.1146/annurev-pathol-020712-163955
pubmed: 23987584
Sevinc M, Karabulut A, Eskazan AE, Catal Tatonyan S, Ozbek U, Soysal T. The impact and prognostic significance of chronic lymphocytic leukemia upregulated 1 (CLLU1) gene expression in patients with chronic lymphocytic leukemia: a single center experience. Lab Med. 2020;51:259–64. https://doi.org/10.1093/labmed/lmz058 .
doi: 10.1093/labmed/lmz058
pubmed: 31589746
Caligaris-Cappio F, Ghia P. The nature and origin of the B-chronic lymphocytic leukemia cell: a tentative model. Hematol Oncol Clin North Am. 2004;18:849–62. https://doi.org/10.1016/j.hoc.2004.04.004 .
doi: 10.1016/j.hoc.2004.04.004
pubmed: 15325702
Chen L, Li J, Zheng W, Zhang Y, Wu Y, Li L, et al. The prognostic evaluation of CLLU1 expression levels in 50 Chinese patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2007;48:1785–92. https://doi.org/10.1080/10428190701534416 .
doi: 10.1080/10428190701534416
pubmed: 17786715
Binet JL, Auquier A, Dighiero G, Chastang C, Piguet H, Goasguen J, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer. 1981;48:198–206. https://doi.org/10.1002/1097-0142(19810701)48:1%3c198::aid-cncr2820480131%3e3.0.co;2-v .
doi: 10.1002/1097-0142(19810701)48:1<198::aid-cncr2820480131>3.0.co;2-v
pubmed: 7237385
Bosch F, Dalla-Favera R. Chronic lymphocytic leukaemia: from genetics to treatment. Nat Rev Clin Oncol. 2019;16:684–701. https://doi.org/10.1038/s41571-019-0239-8 .
doi: 10.1038/s41571-019-0239-8
pubmed: 31278397
Tausch E, Schneider C, Robrecht S, Zhang C, Dolnik A, Bloehdorn J, et al. Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax. Blood. 2020;135:2402–12. https://doi.org/10.1182/blood.2019004492 .
doi: 10.1182/blood.2019004492
pubmed: 32206772
Deaglio S, Vaisitti T, Aydin S, Ferrero E, Malavasi F. In-tandem insight from basic science combined with clinical research: CD38 as both marker and key component of the pathogenetic network underlying chronic lymphocytic leukemia. Blood. 2006;108:1135–44. https://doi.org/10.1182/blood-2006-01-013003 .
doi: 10.1182/blood-2006-01-013003
pubmed: 16621959
Rawstron AC, Bennett FL, O’Connor SJ, Kwok M, Fenton JA, Plummer M, et al. Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia. N Engl J Med. 2008;359:575–83. https://doi.org/10.1056/NEJMoa075290 .
doi: 10.1056/NEJMoa075290
pubmed: 18687638
Buhl AM, Jurlander J, Geisler CH, Pedersen LB, Andersen MK, Josefsson P, et al. CLLU1 expression levels predict time to initiation of therapy and overall survival in chronic lymphocytic leukemia. Eur J Haematol. 2006;76:455–64. https://doi.org/10.1111/j.0902-4441.2005.t01-1-EJH2530.x .
doi: 10.1111/j.0902-4441.2005.t01-1-EJH2530.x
pubmed: 16529606
Gonzalez D, Else M, Wren D, Usai M, Buhl AM, Parker A, et al. CLLU1 expression has prognostic value in chronic lymphocytic leukemia after first-line therapy in younger patients and in those with mutated IGHV genes. Haematologica. 2013;98:274–8. https://doi.org/10.3324/haematol.2012.070201 .
doi: 10.3324/haematol.2012.070201
pubmed: 22899580
pmcid: 3561436
Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018;131:2745–60. https://doi.org/10.1182/blood-2017-09-806398 .
doi: 10.1182/blood-2017-09-806398
pubmed: 29540348
Dohner H, Stilgenbauer S, Benner A, Leupolt E, Krober A, Bullinger L, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000;343:1910–6. https://doi.org/10.1056/NEJM200012283432602 .
doi: 10.1056/NEJM200012283432602
pubmed: 11136261
Buhl AM, Jurlander J, Jorgensen FS, Ottesen AM, Cowland JB, Gjerdrum LM, et al. Identification of a gene on chromosome 12q22 uniquely overexpressed in chronic lymphocytic leukemia. Blood. 2006;107:2904–11. https://doi.org/10.1182/blood-2005-07-2615 .
doi: 10.1182/blood-2005-07-2615
pubmed: 16339396
Josefsson P, Geisler CH, Leffers H, Petersen JH, Andersen MK, Jurlander J, et al. CLLU1 expression analysis adds prognostic information to risk prediction in chronic lymphocytic leukemia. Blood. 2007;109:4973–9. https://doi.org/10.1182/blood-2006-11-054916 .
doi: 10.1182/blood-2006-11-054916
pubmed: 17284524
Smolej L. The prognostic role of CLLU1 in chronic lymphocytic leukaemia. Eur J Haematol. 2006;77:177. https://doi.org/10.1111/j.1600-0609.2006.00694.x .
doi: 10.1111/j.1600-0609.2006.00694.x
pubmed: 16856913
Oppliger Leibundgut E, Rogenmoser-Dissler D, de Beer D, Porret NA, Zibellini S, Durig J, et al. CLLU1 expression distinguishes chronic lymphocytic leukemia from other mature B-cell neoplasms. Leuk Res. 2012;36:1204–7. https://doi.org/10.1016/j.leukres.2012.05.015 .
doi: 10.1016/j.leukres.2012.05.015
pubmed: 22738889
Grzybowska EA, Wakula M. Protein binding to cis-motifs in mRNAs coding sequence is common and regulates transcript stability and the rate of translation. Cells. 2021;10:2910. https://doi.org/10.3390/cells10112910 .
doi: 10.3390/cells10112910
pubmed: 34831133
pmcid: 8616275
Buhl AM, Novotny GW, Josefsson P, Nielsen JE, Pedersen LB, Geisler C, et al. The CLLU1 expression level is a stable and inherent feature of the chronic lymphocytic leukemia clone. Leukemia. 2009;23:1182–6. https://doi.org/10.1038/leu.2009.16 .
doi: 10.1038/leu.2009.16
pubmed: 19212335
pmcid: 5283720
Jebaraj BM, Kienle D, Lechel A, Mertens D, Heuberger M, Ott G, et al. Telomere length in mantle cell lymphoma. Blood. 2013;121:1184–7. https://doi.org/10.1182/blood-2012-08-452649 .
doi: 10.1182/blood-2012-08-452649
pubmed: 23243283
Buhl AM, James DF, Neuberg D, Jain S, Rassenti LZ, Kipps TJ. Analysis of CLLU1 expression levels before and after therapy in patients with chronic lymphocytic leukemia. Eur J Haematol. 2011;86:405–11. https://doi.org/10.1111/j.1600-0609.2011.01588.x .
doi: 10.1111/j.1600-0609.2011.01588.x
pubmed: 21323738
pmcid: 4114228
Matsuda K. PCR-based detection methods for single-nucleotide polymorphism or mutation: real-time PCR and its substantial contribution toward technological refinement. Adv Clin Chem. 2017;80:45–72. https://doi.org/10.1016/bs.acc.2016.11.002 .
doi: 10.1016/bs.acc.2016.11.002
pubmed: 28431642
Shen J, Wang Q, Liang C, Su X, Ke Y, Mao Y, et al. Novel Insights into miR-944 in cancer. Novel Insights Cancers (Basel). 2022;14:4232. https://doi.org/10.3390/cancers14174232 .
doi: 10.3390/cancers14174232
pubmed: 36077769
pmcid: 9454979
Wu L, Qu X. Cancer biomarker detection: recent achievements and challenges. Chem Soc Rev. 2015;44:2963–97. https://doi.org/10.1039/c4cs00370e .
doi: 10.1039/c4cs00370e
pubmed: 25739971
Romero D. MRD to help assess response in CLL. Nat Rev Clin Oncol. 2019;16(2):68. https://doi.org/10.1038/s41571-018-0159-z .
doi: 10.1038/s41571-018-0159-z
pubmed: 30573789
Sampath D, Calin GA. miRs: fine-tuning prognosis in CLL. Blood. 2009;113:5035–6. https://doi.org/10.1182/blood-2009-02-205419 .
doi: 10.1182/blood-2009-02-205419
pubmed: 19470431
Wos J, Szymanska A, Lehman N, Chocholska S, Zarobkiewicz M, Pozarowski P, et al. Can galectin-3 be a novel biomarker in chronic lymphocytic leukemia? Cells. 2023;3:30. https://doi.org/10.3390/cells13010030 .
doi: 10.3390/cells13010030
Hallek M. Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment. Am J Hematol. 2019;94:1266–87. https://doi.org/10.1002/ajh.25595 .
doi: 10.1002/ajh.25595
pubmed: 31364186
Deaglio S, Vaisitti T, Aydin S, Bergui L, D’Arena G, Bonello L, et al. CD38 and ZAP-70 are functionally linked and mark CLL cells with high migratory potential. Blood. 2007;110:4012–21. https://doi.org/10.1182/blood-2007-06-094029 .
doi: 10.1182/blood-2007-06-094029
pubmed: 17699742
Hamblin TJ, Orchard JA, Ibbotson RE, Davis Z, Thomas PW, Stevenson FK, et al. CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease. Blood. 2002;99:1023–9. https://doi.org/10.1182/blood.v99.3.1023 .
doi: 10.1182/blood.v99.3.1023
pubmed: 11807008
Crespo M, Bosch F, Villamor N, Bellosillo B, Colomer D, Rozman M, et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med. 2003;348:1764–75. https://doi.org/10.1056/NEJMoa023143 .
doi: 10.1056/NEJMoa023143
pubmed: 12724482
Wiestner A, Rosenwald A, Barry TS, Wright G, Davis RE, Henrickson SE, et al. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood. 2003;101:4944–51. https://doi.org/10.1182/blood-2002-10-3306 .
doi: 10.1182/blood-2002-10-3306
pubmed: 12595313
Rassenti LZ, Huynh L, Toy TL, Chen L, Keating MJ, Gribben JG, et al. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med. 2004;351:893–901. https://doi.org/10.1056/NEJMoa040857 .
doi: 10.1056/NEJMoa040857
pubmed: 15329427
Rosenwald A, Alizadeh AA, Widhopf G, Simon R, Davis RE, Yu X, et al. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med. 2001;194(11):1639–47. https://doi.org/10.1084/jem.194.11.1639 .
doi: 10.1084/jem.194.11.1639
pubmed: 11733578
pmcid: 2193523
Luna A, Elloumi F, Varma S, Wang Y, Rajapakse VN, Aladjem MI, et al. CellMiner cross-database (CellMinerCDB) version 1.2: exploration of patient-derived cancer cell line pharmacogenomics. Nucleic Acids Res. 2021;49(D1083):D1093. https://doi.org/10.1093/nar/gkaa968 .
doi: 10.1093/nar/gkaa968